D. Eratne, M. Kang, C. Lewis, C. Dang, C. Malpas, M. Keem, J. Grewal, Vladimir Marinov, A. Coe, Cath Kaylor-Hughes, Thomas Borchard, Chhoa Keng-Hong, Alexandra Waxmann, Burcu Saglam, Tomáš Kalinčík, Richard Kanaan, W. Kelso, Andrew Evans, S. Farrand, S. Loi, M. Walterfang, C. Stehmann, Qiao-Xin Li, Steven Collins, C. L. Masters, A. Santillo, Henrik Zetterberg, K. Blennow, S. Berkovic, Dennis Velakoulis, Terence J. O’Brien, Patrick Kwan, O. Hansson, Christopher Fowler, Jane Gunn
{"title":"Plasma and CSF neurofilament light chain distinguish neurodegenerative from primary psychiatric conditions in a clinical setting","authors":"D. Eratne, M. Kang, C. Lewis, C. Dang, C. Malpas, M. Keem, J. Grewal, Vladimir Marinov, A. Coe, Cath Kaylor-Hughes, Thomas Borchard, Chhoa Keng-Hong, Alexandra Waxmann, Burcu Saglam, Tomáš Kalinčík, Richard Kanaan, W. Kelso, Andrew Evans, S. Farrand, S. Loi, M. Walterfang, C. Stehmann, Qiao-Xin Li, Steven Collins, C. L. Masters, A. Santillo, Henrik Zetterberg, K. Blennow, S. Berkovic, Dennis Velakoulis, Terence J. O’Brien, Patrick Kwan, O. Hansson, Christopher Fowler, Jane Gunn","doi":"10.1101/2024.08.11.24311847","DOIUrl":null,"url":null,"abstract":"INTRODUCTION: Many patients with neurodegenerative disorders (ND) face diagnostic delay and misdiagnosis. We investigated blood and cerebrospinal fluid (CSF) neurofilament light chain (NfL) to distinguish ND from primary psychiatric disorders (ND), a common challenge in clinical settings. METHODS: Plasma and CSF NfL levels were measured and compared between groups, adjusting for age, sex, weight. RESULTS: 337 participants included: 136 ND, 77 PPD, 124 Controls. Plasma NfL was 2.5 fold elevated in ND compared to PPD and had strong diagnostic performance (area under the curve, AUC 0.86, 81%/85% specificity/sensitivity) that was comparable to CSF NfL (2 fold elevated, AUC 0.89, 95%/71% specificity/sensitivity). Diagnostic performance was especially strong in younger people (40-<60years). Additional findings were cut-offs optimised for sensitivity and specificity, and issues important for future clinical translation CONCLUSIONS: This study adds important evidence for a simple blood-based biomarker to assist as a screening test for neurodegeneration and distinction from PPD, in clinical settings.","PeriodicalId":18505,"journal":{"name":"medRxiv","volume":"42 9","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.08.11.24311847","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
INTRODUCTION: Many patients with neurodegenerative disorders (ND) face diagnostic delay and misdiagnosis. We investigated blood and cerebrospinal fluid (CSF) neurofilament light chain (NfL) to distinguish ND from primary psychiatric disorders (ND), a common challenge in clinical settings. METHODS: Plasma and CSF NfL levels were measured and compared between groups, adjusting for age, sex, weight. RESULTS: 337 participants included: 136 ND, 77 PPD, 124 Controls. Plasma NfL was 2.5 fold elevated in ND compared to PPD and had strong diagnostic performance (area under the curve, AUC 0.86, 81%/85% specificity/sensitivity) that was comparable to CSF NfL (2 fold elevated, AUC 0.89, 95%/71% specificity/sensitivity). Diagnostic performance was especially strong in younger people (40-<60years). Additional findings were cut-offs optimised for sensitivity and specificity, and issues important for future clinical translation CONCLUSIONS: This study adds important evidence for a simple blood-based biomarker to assist as a screening test for neurodegeneration and distinction from PPD, in clinical settings.